Zymeworks Inc. (ZYME) is a clinical-stage biopharmaceutical company, not an exchange-traded fund, so this analysis centers on sell-side price targets. Fourteen current targets were reviewed, spanning a low of $32 to a high of $58. The arithmetic mean is about $41.60, rounded to a $42 central target. Averages of 14 targets sit between roughly $40.70 and $41.70 across data providers, so $42 fairly represents the collected estimates without being mistaken for a single official consensus.
Sentiment is strikingly one-sided: the available ratings are effectively all Buy, Outperform, or Overweight, with no Hold or Sell ratings in the current set. Yet the wide range shows that agreement on direction does not equal agreement on magnitude. More cautious targets sit in the low-to-mid $30s—J.P. Morgan at $33, Truist and TD Cowen at $34—while H.C. Wainwright ($55), Jefferies ($52), and Leerink Partners ($58) anchor the bullish end. Recent activity has been a steady run of increases: Truist raised its target to $34, Citi to $39, B. Riley to $44, and H.C. Wainwright to $55, among others.
ZYME shares recently traded near $30.80, giving the stock a market capitalization of roughly $2.1 billion. A move to $42 would require about 36% appreciation—properly described as a substantial gain. The shares have already delivered outsized returns, up nearly 87% over the trailing 52 weeks and recently trading within reach of the 52-week high of $31.49.
The path toward the target likely hinges on execution rather than re-rating alone. Zymeworks' lead asset, the HER2-targeting bispecific antibody zanidatamab (marketed through its partner as Ziihera for HER2-positive biliary tract cancer), anchors the pipeline, while the Theravance Biopharma acquisition adds respiratory products and near-term revenue. Management has guided to 2026 revenue of $278 million to $292 million, a sharp step-up from trailing revenue near $37 million, reflecting the acquired portfolio. Delivering on that guide and advancing earlier-stage programs would be the core mechanism for the shares to justify a higher valuation.
The shares recently pressed toward the 52-week high near $31.50, a clear overhead resistance zone; a decisive break above it would open the next notable levels around $32–$33. On the downside, support appears in the $28–$29 area from recent consolidation, with the 50-day moving average near $27.50 and the 200-day moving average near $25.40 providing deeper cushions. The 52-week low sits near $16, underscoring how far the stock has already run and the distance between current prices and any meaningful long-term base.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms rarely publish a uniform horizon, and some targets in the set may reflect longer-range sum-of-the-parts thinking. Investors should watch third-quarter results and any updates to 2026 guidance, clinical and regulatory milestones for zanidatamab, integration progress from the Theravance deal, further analyst revisions, and broader biotech sentiment and interest-rate conditions. Short interest and insider activity are secondary signals worth tracking alongside fundamentals.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For traders following names such as ZYME, the tool can help surface opportunities, track positions, and identify shifting trends more efficiently than manual chart review. Investors interested in supplementing fundamental research with systematic, data-driven timing may find these signals a useful addition to their workflow.
The $42 central target, derived from the mean of 14 analyst targets ranging from $32 to $58, implies roughly 36% upside from a recent price near $30.80. Support rests on sharply higher 2026 revenue guidance, the Theravance acquisition, a clean balance sheet, and a uniformly bullish—and recently rising—analyst consensus. The principal obstacles are a rich trailing valuation, ongoing losses, and genuine execution and clinical risk, reflected in the unusually wide spread between the lowest and highest targets. Investors should focus on third-quarter results, guidance updates, and pipeline milestones rather than treating the $42 figure as a forecast or a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with JAZZ. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then JAZZ could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | +2.11% | ||
| JAZZ - ZYME | 53% Loosely correlated | +0.77% | ||
| REPL - ZYME | 46% Loosely correlated | +4.58% | ||
| ENTA - ZYME | 44% Loosely correlated | -2.18% | ||
| VSTM - ZYME | 44% Loosely correlated | +0.34% | ||
| DYN - ZYME | 42% Loosely correlated | -3.76% | ||
More | ||||